{"id":34651,"date":"2024-11-26T17:06:14","date_gmt":"2024-11-26T17:06:14","guid":{"rendered":"https:\/\/bnssghealthiertogether.org.uk\/?page_id=34651"},"modified":"2024-11-26T17:06:14","modified_gmt":"2024-11-26T17:06:14","slug":"how-can-we-optimise-the-management-of-patients-with-inflammatory-bowel-disease","status":"publish","type":"page","link":"https:\/\/bnssghealthiertogether.org.uk\/tr\/integrated-care-board\/research-and-evidence\/our-research-portfolio\/type-2-rcf-funded-projects\/how-can-we-optimise-the-management-of-patients-with-inflammatory-bowel-disease\/","title":{"rendered":"\u0130ltihapl\u0131 Ba\u011f\u0131rsak Hastal\u0131\u011f\u0131 olan hastalar\u0131n tedavisini nas\u0131l optimize edebiliriz?"},"content":{"rendered":"
Mod\u00fcl-1 ba\u015fl\u0131kl\u0131 b\u00f6l\u00fcm<\/span><\/a>
\r\n
\r\n

\u0130ltihapl\u0131 Ba\u011f\u0131rsak Hastal\u0131\u011f\u0131 olan hastalar\u0131n tedavisini nas\u0131l optimize edebiliriz?<\/h1>\n

\u00d6nerilen ara\u015ft\u0131rma sorusu nedir?<\/h2>\n

\u0130ltihapl\u0131 Ba\u011f\u0131rsak Hastal\u0131\u011f\u0131 olan hastalar\u0131n tedavisini nas\u0131l optimize edebiliriz?<\/p>\n

Finansman<\/h2>\n

BNSSG ICB Ara\u015ft\u0131rma Kapasitesi Geli\u015ftirme Fonu.<\/p>\n

Sorun nedir?<\/h2>\n

\u0130ltihapl\u0131 ba\u011f\u0131rsak hastal\u0131\u011f\u0131 (IBD), Crohn hastal\u0131\u011f\u0131 (CD) ve \u00fclseratif kolit (UC), \u0130ngiltere'de 500.000 (1:123) ki\u015fiyi etkileyen kronik ba\u011f\u0131rsak iltihab\u0131 hastal\u0131klar\u0131d\u0131r. IBD, genellikle 10 ila 30 ya\u015flar\u0131 aras\u0131ndaki gen\u00e7lerde te\u015fhis edilen, \u00f6m\u00fcr boyu s\u00fcren bir hastal\u0131kt\u0131r ve \u00f6nemli \u00f6l\u00e7\u00fcde sakatl\u0131\u011fa yol a\u00e7arak normal \u00e7al\u0131\u015fma yetene\u011fini s\u0131kl\u0131kla k\u0131s\u0131tlar.<\/p>\n

\u0130nflamatuvar ba\u011f\u0131rsak hastal\u0131\u011f\u0131n\u0131n (IBD) t\u0131bbi tedavisi, yakla\u015f\u0131k 30 y\u0131l \u00f6nce ilk biyolojik tedavi olan infliximab'\u0131n piyasaya s\u00fcr\u00fclmesiyle devrim niteli\u011finde bir de\u011fi\u015fime u\u011frad\u0131. O zamandan beri, IBD'de kullan\u0131lmak \u00fczere \u00e7e\u015fitli biyolojik ve k\u00fc\u00e7\u00fck molek\u00fcll\u00fc tedaviler geli\u015ftirilmi\u015ftir.<\/p>\n

Tedavi se\u00e7eneklerindeki art\u0131\u015fa kar\u015f\u0131l\u0131k, doktorlara hangi ila\u00e7lar\u0131 \u00f6nce kullanmalar\u0131 gerekti\u011fi ve tedavi ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 durumunda ila\u00e7lar aras\u0131nda nas\u0131l ilerlemeleri gerekti\u011fi konusunda yol g\u00f6sterecek bir literat\u00fcr bulunmamaktad\u0131r. \u00d6n veriler, re\u00e7ete yazma uygulamalar\u0131nda \u00f6nemli farkl\u0131l\u0131klar oldu\u011funu ve mevcut literat\u00fcr\u00fcn kaynak kullan\u0131m\u0131n\u0131 optimize etmemize olanak tan\u0131mad\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. Bu durum, hastalar i\u00e7in iyile\u015fmeyi geciktirir ve \u00f6nemli miktarda kaynak israf\u0131na yol a\u00e7ar.<\/p>\n

Ara\u015ft\u0131rman\u0131n amac\u0131 nedir?<\/h2>\n

Klinik etkinlik, maliyet etkinli\u011fi ve hasta deneyimine dayanarak, inflamatuar ba\u011f\u0131rsak hastal\u0131\u011f\u0131n\u0131n y\u00f6netimi i\u00e7in biyolojik ve k\u00fc\u00e7\u00fck molek\u00fcll\u00fc tedavilerin \u00f6nceliklendirilmesine y\u00f6nelik bir yol haritas\u0131 geli\u015ftirmek.<\/p>\n

Bu nas\u0131l ba\u015far\u0131lacak?<\/h2>\n

\u00d6ncelikle, BNSSG genelinde iltihapl\u0131 ba\u011f\u0131rsak hastal\u0131\u011f\u0131 hastalar\u0131n\u0131n bak\u0131m\u0131n\u0131, yerel re\u00e7ete yaz\u0131m\u0131na ve b\u00f6lgeye ve hasta demografisine g\u00f6re farkl\u0131l\u0131klara odaklanarak a\u00e7\u0131klayaca\u011f\u0131z.<\/p>\n

\u0130kinci olarak, iltihaplanmay\u0131 incelemek i\u00e7in kan ve d\u0131\u015fk\u0131 belirte\u00e7leri gibi klinik sonu\u00e7lara ili\u015fkin verilerin yan\u0131 s\u0131ra hastaneye yat\u0131\u015flar, steroid k\u00fcrleri ve ameliyat gibi yan etkileri de toplayaca\u011f\u0131z. Bu veriler, tedavi stratejilerini kar\u015f\u0131la\u015ft\u0131rmak ve bu ila\u00e7lar\u0131n klinik etkinli\u011fi hakk\u0131nda deneme ortam\u0131nda bilinenleri desteklemek i\u00e7in ger\u00e7ek d\u00fcnya verileri sa\u011flamak amac\u0131yla kullan\u0131lacakt\u0131r.<\/p>\n

\u00dc\u00e7\u00fcnc\u00fcs\u00fc, maliyet etkinli\u011fi 'remisyon ba\u015f\u0131na maliyet' hesaplanarak de\u011ferlendirilebilir. Ek ba\u011flam sa\u011flamak i\u00e7in, ba\u015far\u0131s\u0131z tedaviler i\u00e7in ortaya \u00e7\u0131kan sonraki klinik temaslar\u0131n maliyetini ve her tedaviyle ilgili olumsuz klinik sonu\u00e7lar\u0131 da dahil edece\u011fiz.<\/p>\n

Son olarak, hasta deneyimlerini incelemek, \u00f6nemli hasta sonu\u00e7lar\u0131n\u0131 belirlemek ve bu ila\u00e7larla tedavi edilen hastalar\u0131n kar\u015f\u0131la\u015ft\u0131\u011f\u0131 yayg\u0131n zorluklar\u0131 vurgulamak amac\u0131yla hasta g\u00f6r\u00fc\u015fmelerinden yararlanaca\u011f\u0131z; bu s\u00fcre\u00e7te sa\u011fl\u0131k e\u015fitsizliklerini de ele alaca\u011f\u0131z.<\/p>\n

Ara\u015ft\u0131rmay\u0131 kim y\u00fcr\u00fct\u00fcyor?<\/h2>\n

Dr. Jennifer Phillips, Akademik Klinik Ara\u015ft\u0131rma G\u00f6revlisi, Gastroenteroloji Uzman\u0131.<\/p>\n

Daha fazla bilgi:<\/h2>\n

Daha fazla bilgi almak veya bu projeye dahil olmak i\u00e7in l\u00fctfen bnssg.research@nhs.net adresinden ileti\u015fime ge\u00e7in.<\/p>\n <\/div>\r\n <\/section><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

Section titled module-1 How can we optimise the management of patients with Inflammatory Bowel Disease? What is the proposed research question? How can we optimise the management of patients with Inflammatory Bowel Disease? Funding BNSSG ICB Research Capability Funding. What is the problem? Inflammatory bowel disease (IBD), Crohn\u2019s Disease (CD) and ulcerative colitis (UC), are […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":32896,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"tags":[],"class_list":["post-34651","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/34651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/comments?post=34651"}],"version-history":[{"count":1,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/34651\/revisions"}],"predecessor-version":[{"id":34652,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/34651\/revisions\/34652"}],"up":[{"embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/pages\/32896"}],"wp:attachment":[{"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/media?parent=34651"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bnssghealthiertogether.org.uk\/tr\/wp-json\/wp\/v2\/tags?post=34651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}